Erdomed Muko is a medicinal product in the form of a powder for oral suspension. The preparation is administered to adults and children over 12 years of age to thin and facilitate the expectoration of mucous secretions from the respiratory tract.
Children over 12 years of age:
1 sachet 2 times a day.
Adults:
1 sachet 2 or 3 times a day.
1 sachet contains 225 mg of erdosteine (Erdosteinum).
Auxiliary substances:
Sucrose, Sodium starch glycolate (type A, Silicon dioxide, Sucralose (E 955), Anhydrous malic acid, Orange flavor [maize maltodextrin, flavorings, α-tocopherol (E 307)]
Adjunctive therapy in acute and chronic inflammatory diseases of the respiratory tract (nose, paranasal sinuses, larynx, trachea, bronchi and lungs) associated with excessive secretion of mucus.
Hypersensitivity to the active substance or to any of the excipients, or to substances containing free SH groups.
Hepatic impairment (e.g. increased serum alkaline phosphatase, increased serum transaminases).
Renal failure (creatinine clearance <25 ml / min) 2
Homocystinuria (erdosteine is partially metabolized to homocysteine, and there are no data describing the administration of erdosteine in patients with inherited disorders of amino acid metabolism, especially in patients on a diet that excludes methionine).
Do not use in children under 12 years of age.
Gastrointestinal adverse reactions such as heartburn, nausea, diarrhea have been reported in a few cases after the administration of erdosteine. Disturbance or an abnormal taste at the beginning of treatment has been reported in a few cases.
In case of typical complaints and symptoms of hypersensitivity, treatment should be discontinued immediately.
Erdomed Muko should not be used concomitantly with antitussive preparations.
Use with caution in patients with a weakened cough reflex or impaired ciliary clearance (due to the risk of accumulating large amounts of mucus).
Erdomed Muko contains sucrose, therefore patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicinal product.
One sachet contains 3.5 g of sucrose. This should be taken into account in diabetic patients.
Use of other medications
No clinically significant adverse interactions have been observed with other preparations used to treat respiratory tract infections and chronic obstructive pulmonary disease such as theophylline, preparations that relax bronchial smooth muscle (steroid therapy), erythromycin, amoxicillin or co-trimoxazole. After administration of erdosteine, an increase in the concentration of amoxicillin in the respiratory tract has been shown.
Concomitant treatment with preparations that reduce the cough reflex (antitussive preparations) may cause the accumulation of large amounts of bronchial secretions, which may lead to the deterioration of the patient's condition in the course of the disease, e.g. due to deterioration of respiratory function.
To avoid complications, antitussive preparations and secretolytic preparations should not be routinely combined, especially before bedtime.
Pregnancy and breastfeeding
There are no clinical data on the use of erdostein during pregnancy. Animal studies do not indicate direct or indirect harmful effects on pregnancy, embryo / fetal development, parturition or postnatal development. Nevertheless, the use of the product by pregnant or breastfeeding women is not recommended.
Use of the preparation in children and adolescents
Do not use in children under 12 years of age.